tirzepatide for kidney disease improves outcomes in T2DM with increased CV risk Tirzepatide and Chronic Kidney Disease:

2002 Oct;26(6):713-28

In prostate cancer, GLP-1R expression is relatively limited, but metabolic modulation by GLP-1RAs may confer indirect protective effects via inhibition of the PI3K/Akt pathway [341]

Four percent discontinued owing to a treatment-related TEAE, and 1% (2 patients) discontinued because of respiratory depression with decreased oxygen saturation

Defensive : Proactively fortifies your immune system to guard against chronic diseases and autoimmune flare-ups

& Mielgo-Ayuso, J

Of note, in STEP 3 intensive behavioral treatment was also administered in both arms, and in STEP 4 all patients were initially assigned to semaglutide 2.4 mg but were randomized 2:1 to semaglutide 2.4 or placebo after 20 weeks 25